Health and Healthcare

Amgen : AMGN

All Amgen Articles

720 Articles

Chris Lange | Apr 12, 2017 at 9:10 AM EDT

Short Sellers Back Off Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased in most of…

Chris Lange | Mar 27, 2017 at 10:30 AM EDT

Short Interest Pulls Back in Major Biotechs

The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of…

Chris Lange | Mar 10, 2017 at 10:30 AM EST

Major Biotechs See a Retreat in Short Interest

The February 28 short interest data have been compared with the previous report, and short interest decreased in most of…

Jon C. Ogg | Mar 9, 2017 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.

Chris Lange | Feb 28, 2017 at 10:15 AM EST

Short Sellers Hike Their Bets in Major Biotechs

The February 15 short interest data have been compared with the previous report, and short interest increased in all the…

Lee Jackson | Feb 23, 2017 at 8:15 AM EST

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is…

Jon C. Ogg | Feb 22, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Broadcom, Canadian Solar, Goldman Sachs, TripAdvisor, Wal-Mart and More

The top analyst upgrades, downgrades and initiations seen on Wednesday include Broadcom, Canadian Solar, Goldman Sachs, TripAdvisor and Wal-Mart.

Chris Lange | Feb 10, 2017 at 9:55 AM EST

Major Biotechs Scare Off Loads of Short Sellers

As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears…

Chris Lange | Feb 2, 2017 at 4:43 PM EST

Why Amgen Earnings Are So Incredible

Amgen Inc. (NASDAQ: AMGN) reported its fourth-quarter financial results after the markets closed on Thursday. This biotech giant posted $2.89…

Chris Lange | Feb 1, 2017 at 3:11 PM EST

Top 6 Earnings To Watch For On Thursday

Although this earnings season has been relatively positive, the Dow has stepped away from its 20,000 mark, and it seems…

Jon C. Ogg | Feb 1, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Amgen, Apple, Corning, Mobileye, Under Armour, Electronic Arts and Many More

The top analyst upgrades, downgrades and initiations seen on Wednesday include Amgen, Apple, Corning, Mobileye, Under Armour and Electronic Arts.

Chris Lange | Jan 26, 2017 at 10:35 AM EST

Short Sellers Back Off Major Biotechs

As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears…

Lee Jackson | Jan 23, 2017 at 9:55 AM EST

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks…

Chris Lange | Jan 12, 2017 at 9:35 AM EST

Biotech Short Sellers Run for Cover

As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what…

Chris Lange | Jan 6, 2017 at 11:55 AM EST

Friday’s 6 Biopharma Movers That Can’t Be Ignored

2017 could be different for the health care sector. It is very possible that this new administration could lead to…

1 … 20 21 22 23 24 … 48

Amgen : AMGN

All Amgen Articles

Short Sellers Back Off Major Biotechs

Short Interest Pulls Back in Major Biotechs

Major Biotechs See a Retreat in Short Interest

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Short Sellers Hike Their Bets in Major Biotechs

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

Top Analyst Upgrades and Downgrades: Broadcom, Canadian Solar, Goldman Sachs, TripAdvisor, Wal-Mart and More

Major Biotechs Scare Off Loads of Short Sellers

Why Amgen Earnings Are So Incredible

Top 6 Earnings To Watch For On Thursday

Top Analyst Upgrades and Downgrades: Amgen, Apple, Corning, Mobileye, Under Armour, Electronic Arts and Many More

Short Sellers Back Off Major Biotechs

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Friday’s 6 Biopharma Movers That Can’t Be Ignored

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Amgen : AMGN

All Amgen Articles

Short Sellers Back Off Major Biotechs

Short Interest Pulls Back in Major Biotechs

Major Biotechs See a Retreat in Short Interest

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Short Sellers Hike Their Bets in Major Biotechs

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

Top Analyst Upgrades and Downgrades: Broadcom, Canadian Solar, Goldman Sachs, TripAdvisor, Wal-Mart and More

Major Biotechs Scare Off Loads of Short Sellers

Why Amgen Earnings Are So Incredible

Top 6 Earnings To Watch For On Thursday

Top Analyst Upgrades and Downgrades: Amgen, Apple, Corning, Mobileye, Under Armour, Electronic Arts and Many More

Short Sellers Back Off Major Biotechs

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Friday’s 6 Biopharma Movers That Can’t Be Ignored

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Featured Reads

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.